These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 26712559)

  • 1. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Dick AD; Tundia N; Sorg R; Zhao C; Chao J; Joshi A; Skup M
    Ophthalmology; 2016 Mar; 123(3):655-62. PubMed ID: 26712559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vision-threatening complications in childhood uveitis].
    Mingels A; Hudde T; Heinz C; Heiligenhaus A
    Ophthalmologe; 2005 May; 102(5):477-84. PubMed ID: 15711944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
    Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
    Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular complications of pediatric uveitis.
    Rosenberg KD; Feuer WJ; Davis JL
    Ophthalmology; 2004 Dec; 111(12):2299-306. PubMed ID: 15582090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis.
    Thorne JE; Skup M; Tundia N; Macaulay D; Revol C; Chao J; Joshi A; Dick AD
    Acta Ophthalmol; 2016 Aug; 94(5):e331-9. PubMed ID: 26932535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
    Kempen JH; Van Natta ML; Friedman DS; Altaweel MM; Ansari H; Dunn JP; Elner SG; Holbrook JT; Lim LL; Sugar EA; Jabs DA;
    Am J Ophthalmol; 2020 Nov; 219():303-316. PubMed ID: 32628922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uveitic foveal atrophy: clinical features and associations.
    Forooghian F; Yeh S; Faia LJ; Nussenblatt RB
    Arch Ophthalmol; 2009 Feb; 127(2):179-86. PubMed ID: 19204236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis.
    Chirikov VV; Shah R; Kwon Y; Patel D
    Ophthalmic Epidemiol; 2019 Feb; 26(1):27-46. PubMed ID: 30199301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric Non-Infectious Uveitis: Long-Term Outcomes and Complications.
    Markomichelakis NN; Aissopou EK; Chatzistefanou KI
    Ocul Immunol Inflamm; 2023 Dec; 31(10):2001-2008. PubMed ID: 36693268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninfectious Intermediate, Posterior, or Panuveitis: Results from the Retrospective, Observational, International EyeCOPE Study.
    Kramer M; Brichova M; Tugal-Tutkun I; Panchenko M; Gormezano N; Koenigsbauer F; Franco P; Muccioli C; Hasanreisoglu M;
    Ophthalmol Ther; 2021 Sep; 10(3):565-580. PubMed ID: 34117983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association between Noninfectious Uveitis and Coronavirus Disease 2019 Outcomes: An Analysis of United States Claims-Based Data.
    Miller DC; Sun Y; Chen EM; Arnold BF; Acharya NR
    Ophthalmology; 2022 Mar; 129(3):334-343. PubMed ID: 34648828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors in uveitis].
    Albaroudi N; Tijani M; Boutimzine N; Cherkaoui O; Laghmari M
    J Fr Ophtalmol; 2017 Nov; 40(9):751-757. PubMed ID: 28882393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmic Manifestations and Causes of Vision Impairment in Ebola Virus Disease Survivors in Monrovia, Liberia.
    Shantha JG; Crozier I; Hayek BR; Bruce BB; Gargu C; Brown J; Fankhauser J; Yeh S
    Ophthalmology; 2017 Feb; 124(2):170-177. PubMed ID: 27914832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of co-morbid eye disease in patients with chronic renal failure: a population-based study.
    Wang TJ; Wu CK; Hu CC; Keller JJ; Lin HC
    Ophthalmic Epidemiol; 2012 Jun; 19(3):137-43. PubMed ID: 22568426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complications in Intermediate Uveitis: Prevalence, Time of Onset, and Effects on Vision in Short-Term and Long-Term Follow-Up.
    Sancho L; Kramer M; Koriat A; Eiger-Moscovich M; Sharon Y; Amer R
    Ocul Immunol Inflamm; 2019; 27(3):447-455. PubMed ID: 29370567
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
    Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of uveitis in children over a 10-year period.
    Clarke LA; Guex-Crosier Y; Hofer M
    Clin Exp Rheumatol; 2013; 31(4):633-7. PubMed ID: 23432940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
    ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
    Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.